Immuneering Corporation Announces Interim Data from Phase 2a Clinical Trial of Atebimetinib in Pancreatic Cancer Patients

Strategic Insights -

Immuneering Corporation, a biotechnology company, has announced interim data from its ongoing Phase 2a clinical trial evaluating atebimetinib, a once-daily oral MEK inhibitor, in combination with modified Gemcitabine/nab-Paclitaxel (mGnP) in first-line pancreatic cancer patients. As of May 26, 2025, of the 36 response evaluable patients in the mGnP arm, one patient achieved a complete response, 13 patients achieved a partial response, 15 patients achieved stable disease, and seven patients showed progressive disease, representing an interim 81% disease control rate (DCR) and an interim 39% overall response rate (ORR). The company also reported that atebimetinib in combination with mGnP was generally well tolerated, with Grade 3 treatment-emergent adverse events (TEAEs) observed in 10% or greater of patients.

Key Takeaways:

  • Interim data from the Phase 2a clinical trial of atebimetinib in combination with mGnP in first-line pancreatic cancer patients demonstrated a 81% disease control rate (DCR) and a 39% overall response rate (ORR).
  • Of the 36 response evaluable patients, one patient achieved a complete response, 13 patients achieved a partial response, 15 patients achieved stable disease, and seven patients showed progressive disease.
  • Atebimetinib in combination with mGnP was generally well tolerated, with Grade 3 TEAEs observed in 10% or greater of patients, including Anemia (18%) and Neutropenia (15%).
  • No Grade 5 TEAEs were observed in the subset of patients receiving the 240 mg or 320 mg once-daily dose of atebimetinib.
  • The company plans to initiate a pivotal trial evaluating atebimetinib in combination with mGnP in first-line pancreatic cancer patients in 2026, pending regulatory feedback.
  • Additional data from the Phase 2a portion of the atebimetinib Phase 1/2a trial is expected in the fourth quarter of 2025.

Statistics:

  • 36 response evaluable patients in the mGnP arm received atebimetinib (24 patients at 240 mg and 12 patients at 320 mg).
  • 81% disease control rate (DCR) observed in the mGnP arm, indicating stable disease in 15 patients, partial response in 13 patients, and progressive disease in 7 patients.
  • 39% overall response rate (ORR) observed in the mGnP arm, indicating a complete response in 1 patient and partial response in 13 patients.
  • 94% overall survival (OS) observed in the intent-to-treat population of 34 patients dosed at 320 mg ITT Population, with a median follow-up time of six months.
  • 72% progression-free survival (PFS) observed in the intent-to-treat population of 34 patients dosed at 320 mg ITT Population, with a median follow-up time of six months.

Sources:

  • UNITED STATES SECURITIES AND EXCHANGE COMMISSION
  • Form 8-K Current Report, Immuneering Corporation, filed July 17, 2025.
  • Annual Report on Form 10-K, Immuneering Corporation, filed with the SEC on March 20, 2025.
  • Quarterly Report on Form 10-Q, Immuneering Corporation, filed with the SEC on May 5, 2025.